

ESMO PRECEPTORSHIP PROGRAMME

LUNG CANCER

Daily clinical practice, present and future

Rabat, Morocco
26-27 January 2024

CO-CHAIRS Mounir Bachouchi, Morocco
Jaafar Bennouna, France
Hassan Errihani, Morocco
Céline Mascaux, France

SPEAKERS Nadia Benchakroun, Morocco
Souheil Boubia, Morocco
Ibrahim El Ghissassi, Morocco
Basma El Khannoussi, Morocco
Gamaz Malika, Algeria
Nesrine Mejri, Tunisia
Laura Mezquita, Spain

LEARNING OBJECTIVES

- To select the best treatment in a multidisciplinary approach for early stage Non-Small Cell Lung cancer (NSCLC)
- To identify molecular alterations driving the management of metastatic NSCLC
- To learn about the best strategy for metastatic NSCLC with targetable molecular alterations
- To learn about the best strategy for metastatic NSCLC eligible for immunotherapy
- To learn about the best strategy for SCLC

Friday, 26 January 2024

09:00-09:20 20'	Opening and welcome	
10'	Welcome from ESMO and course introduction	Mounir Bachouchi, MA
10'	Overview of Lung Cancer in Morocco	Hassan Errihani, MA
09:20-10:40 80'	SESSION 1 Diagnostics for lung cancer	
20'	Role of EBUS-TBNA	Souheil Boubia, MA
25'	Role of pathologist	Basma El Khannoussi, MA
25'	Role of molecular biologist	Céline Mascaux, FR
10'	Q&A	All
10:40-11:10	Coffee break	

11:10-12:20 70'	SESSION 2 Radical treatment for early stage NSCLC	
30'	Surgery for early stage NSCLC	Souheil Boubia, MA
30'	Stereotactic ablative RT for early stage NSCLC	Nadia Benchakroun, MA
10'	Q&A	All

12:20-13:40 80'	SESSION 3 – Part I Multimodality for localized NSCLC	
50'	Controversies for peri-operative treatment <ul style="list-style-type: none"> - Adjuvant treatment - Neo-adjuvant treatment 	Mounir Bachouchi, MA Jaafar Bennouna, FR
10'	Q&A	All
20'	Participant clinical case discussion (x2)	Faculty

13:40-14:40	Lunch	
--------------------	--------------	--

14:40-16:00 80'	SESSION 3 – Part II Multimodality therapy for localized NSCLC	
30'	Chemoradiation for locally advanced NSCLC	TBC
30'	Management of oligometastatic disease	Laura Mezquita, ES
10'	Q&A	All
10'	Participant clinical case discussion (x1)	Faculty

16:00-16:30	Coffee break	
--------------------	---------------------	--

16:30-18:20 110'	SESSION 4 Advanced NSCLC	
30'	First-line treatment for advanced NSCLC without oncogenic addiction	Céline Mascaux, FR
20'	Second line treatment for advanced NSCLC	Nesrine Mejri, TN
20'	Best strategy for advanced NSCLC with KRAS mutation	Laura Mezquita, ES
10'	Q&A	All
30'	Participant clinical case discussion (x3)	Faculty

20:30	Dinner	
--------------	---------------	--

Saturday, 27 January 2024

09:00-10:40 100'	SESSION 5 Advanced NSCLC with oncogenic addiction	
30'	Treatment of NSCLC with EGFR mutations	Ibrahim El Ghissassi, MA
30'	Treatment of NSCLC positive for ALK or ROS	Hassan Errihani, MA
30'	Beyond EGFR, ALK, ROS: Other molecular alterations	Jaafar Bennouna, FR
10'	Q&A	All

10:40-11:10	Coffee break	
-------------	--------------	--

11:10-12:50 100'	SESSION 6 Small Cell Lung Cancer	
30'	Indications of radiotherapy in localized and advanced SCLC	TBC
30'	Chemotherapy and/or immunotherapy for localized and advanced SCLC	Gamaz Malika, DZ
10'	Q&A	All
30'	Participant clinical case discussion (x3)	Faculty

12:50-13:00 10'	Conclusion and farewell	
--------------------	-------------------------	--

13:00-14:00	Lunch	
-------------	-------	--

Note: Each 10 minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion